Celularity Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Celularity Inc. (Nasdaq: CELU), a clinical-stage biotech firm, announced that CEO Robert Hariri will participate in investor conferences. He will engage in fireside chats at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 1:30 p.m. ET, and the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 12:20 p.m. ET. Live webcasts will be available on Celularity's website and archived for 30 days post-event.

Celularity focuses on developing placental-derived cell therapies for cancer and other diseases.

FLORHAM PARK, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, will participate in fireside chats at the following investor conferences:

• H.C. Wainwright 24^th Annual Global Investment Conference on Monday, September 12, 2022, at 1:30 p.m. ET
  
  
• Morgan Stanley 20^th Annual Global Healthcare Conference on Wednesday, September 14, 2022, at 12:20 p.m. ET
  

A live webcast of the fireside chats can be accessed on the Investors section of Celularity’s website at https://celularity.com/investor-relations/. A replay of the webcasts will be archived and available following the event for approximately 30 days.

About Celularity
Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs). These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
To learn more, visit celularity.com.

Celularity Investor Contacts:
Carlos Ramirez SVP, Investor Relations
Celularity Inc.
carlos.ramirez@celularity.com

FAQ

What is Celularity's stock symbol?

Celularity's stock symbol is CELU.

When will Celularity's CEO participate in investor conferences?

Robert Hariri will participate in two conferences: the H.C. Wainwright Conference on September 12, 2022, and the Morgan Stanley Conference on September 14, 2022.

How can I watch the live webcasts of Celularity's investor conferences?

The live webcasts for Celularity's investor conferences can be accessed on the Investors section of their website.

What therapies is Celularity developing?

Celularity is developing allogeneic placental-derived cell therapies targeting cancer, infectious, and degenerative diseases.